CL2014001719A1 - Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina. - Google Patents

Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina.

Info

Publication number
CL2014001719A1
CL2014001719A1 CL2014001719A CL2014001719A CL2014001719A1 CL 2014001719 A1 CL2014001719 A1 CL 2014001719A1 CL 2014001719 A CL2014001719 A CL 2014001719A CL 2014001719 A CL2014001719 A CL 2014001719A CL 2014001719 A1 CL2014001719 A1 CL 2014001719A1
Authority
CL
Chile
Prior art keywords
bone loss
alveolar bone
antisclerostin antibody
treating alveolar
antisclerostin
Prior art date
Application number
CL2014001719A
Other languages
English (en)
Inventor
Hua Zhu Ke
Min Liu
William V Giannobile
Original Assignee
Amgen Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001719(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Univ Michigan filed Critical Amgen Inc
Publication of CL2014001719A1 publication Critical patent/CL2014001719A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2014001719A 2011-12-28 2014-06-25 Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina. CL2014001719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161580964P 2011-12-28 2011-12-28

Publications (1)

Publication Number Publication Date
CL2014001719A1 true CL2014001719A1 (es) 2014-11-03

Family

ID=47429046

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001719A CL2014001719A1 (es) 2011-12-28 2014-06-25 Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina.

Country Status (20)

Country Link
US (3) US9657090B2 (es)
EP (2) EP2797953B1 (es)
JP (3) JP6363954B2 (es)
KR (3) KR20200056473A (es)
CN (2) CN104039828B (es)
AR (1) AR089509A1 (es)
AU (3) AU2012362898B2 (es)
BR (1) BR112014016108A2 (es)
CA (1) CA2858974A1 (es)
CL (1) CL2014001719A1 (es)
EA (2) EA036740B1 (es)
ES (1) ES2813524T3 (es)
HK (1) HK1198367A1 (es)
IL (2) IL232942B (es)
IN (1) IN2014CN04634A (es)
MX (1) MX354270B (es)
SG (2) SG11201403718YA (es)
TW (3) TW202114733A (es)
WO (1) WO2013101451A1 (es)
ZA (1) ZA201404610B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
TWI636993B (zh) * 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
CR20160147A (es) 2011-03-25 2016-08-03 Amgen Inc Formulaciones de anticuerpos
KR20200056473A (ko) * 2011-12-28 2020-05-22 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6437914B2 (ja) * 2013-07-19 2018-12-12 株式会社 アクシオン・ジャパン パノラマ画像撮影装置及び同装置で用いる画像診断方法
DK3269735T3 (da) * 2015-03-13 2020-12-14 Jiangsu Hengrui Medicine Co Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
US20210198672A1 (en) * 2018-02-12 2021-07-01 Aptacure Therapeutics Limited Aptamer for sclerostin and use thereof
US12062170B2 (en) * 2018-10-30 2024-08-13 Diagnocat Inc System and method for classifying a tooth condition based on landmarked anthropomorphic measurements
US20220122261A1 (en) * 2018-10-30 2022-04-21 Diagnocat Inc. Probabilistic Segmentation of Volumetric Images
IL296545A (en) * 2020-03-26 2022-11-01 Bone Sci Bio Ltd Pharmaceutical preparations containing amphiphilic peptides and methods of using them
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
CN118146384A (zh) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
JPH0647532B2 (ja) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− 歯槽骨吸収の治療
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
AU662304B2 (en) 1990-10-22 1995-08-31 Fox Chase Cancer Center DNA construct for providing RNA therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5863738A (en) 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
KR20000015893A (ko) 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
EP1367124A1 (en) 1997-08-01 2003-12-03 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
AU4595399A (en) 1998-06-19 2000-01-10 Mcgill University Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
ATE444971T1 (de) 1999-06-09 2009-10-15 Genentech Inc Zusammensetzungen und verfahren für die tumor- behandlung
JP2003525611A (ja) 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用
WO2001092308A2 (en) 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
EP1366156A2 (en) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Osteolevin gene polymorphisms
JP4451059B2 (ja) 2000-09-01 2010-04-14 ジェネンテック インコーポレイテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
JP4467304B2 (ja) 2001-12-06 2010-05-26 バイオコントロール システムズ，インコーポレイティド サンプル収集および試験システム
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2004098491A2 (en) 2002-11-01 2004-11-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
WO2004060425A2 (en) * 2002-12-27 2004-07-22 Angiotech International Ag Compositions and methods of using collagen and mmpi
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
GB0304030D0 (en) 2003-02-21 2003-03-26 King S College London Teeth
PT1608399E (pt) 2003-03-14 2012-04-13 Ucb Mfg Inc Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0324854D0 (en) 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007080129A1 (en) 2006-01-13 2007-07-19 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
US20100028335A1 (en) 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
CN101646457B (zh) 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2209491B1 (en) 2007-11-02 2015-10-28 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
WO2010004179A2 (fr) 2008-06-30 2010-01-14 France Telecom Communications cooperatives multicellulaires dans un reseau decentralise
GB0903689D0 (en) 2009-03-03 2009-04-15 Sigmavision Ltd Vehicle tyre measurement
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
US20130138221A1 (en) * 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
SG185465A1 (en) * 2010-05-14 2012-12-28 Amgen Inc High concentration antibody formulations
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
KR20200056473A (ko) * 2011-12-28 2020-05-22 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법

Also Published As

Publication number Publication date
US9913900B2 (en) 2018-03-13
EA202091676A1 (ru) 2021-01-29
EP2797953B1 (en) 2020-06-03
IL232942A0 (en) 2014-07-31
ES2813524T3 (es) 2021-03-24
JP2017214359A (ja) 2017-12-07
AU2012362898B2 (en) 2017-11-09
TW201811364A (zh) 2018-04-01
IL259939B (en) 2020-05-31
US20170281761A1 (en) 2017-10-05
AU2018200649A1 (en) 2018-02-15
KR20200056473A (ko) 2020-05-22
US20180169234A1 (en) 2018-06-21
TW201330859A (zh) 2013-08-01
JP2019031567A (ja) 2019-02-28
KR102033669B1 (ko) 2019-10-18
US20140314776A1 (en) 2014-10-23
MX354270B (es) 2018-02-21
IL232942B (en) 2018-10-31
AR089509A1 (es) 2014-08-27
IN2014CN04634A (es) 2015-09-18
HK1198367A1 (en) 2015-04-10
KR20190120401A (ko) 2019-10-23
TW202114733A (zh) 2021-04-16
TWI706787B (zh) 2020-10-11
WO2013101451A8 (en) 2014-06-26
ZA201404610B (en) 2017-11-29
CN104039828B (zh) 2017-07-21
EA036740B1 (ru) 2020-12-15
EA201491286A1 (ru) 2014-09-30
SG11201403718YA (en) 2014-07-30
EP2797953A1 (en) 2014-11-05
WO2013101451A1 (en) 2013-07-04
EP3712168A3 (en) 2020-10-14
EP3712168A2 (en) 2020-09-23
CN104039828A (zh) 2014-09-10
CA2858974A1 (en) 2013-07-04
AU2019275548A1 (en) 2020-01-02
SG10201509629QA (en) 2015-12-30
MX2014007965A (es) 2014-11-25
JP2015504887A (ja) 2015-02-16
BR112014016108A2 (pt) 2018-09-11
KR20140116089A (ko) 2014-10-01
US9657090B2 (en) 2017-05-23
CN107126560A (zh) 2017-09-05
JP6363954B2 (ja) 2018-07-25
AU2012362898A1 (en) 2014-07-24
IL259939A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2014001719A1 (es) Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina.
BR112013013076A2 (pt) Método para operar elevadores
CL2014000731A1 (es) Metodo para producir derivados de 4,4-difluoro-3,4-dihidroisoquinolina
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
BR112014014583A2 (pt) método para produção de uma ração animal, e, ração animal
BR112015004487A2 (pt) método limpo para preparar d, l-metionina
BR112013019637A2 (pt) sistemas, aparelho e métodos para implantação de implantes
BR112014006919A2 (pt) método para intensificar o crescimento de plantas
BR112013029507A2 (pt) método para tratar uma doença ou um distúrbio
BR112013033167A2 (pt) método, e, aparelho
BR112013016491A2 (pt) método para tratamento de têxtil
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
BR112014005422A2 (pt) suplemento de micronutriente, e, método para fazer o mesmo
BR112013007237A2 (pt) ''método para produzir um anticorpo anti-ig-1r''
BR112014023401A2 (pt) método para produzir batoque de perfuração-laminação
BR112013021775A2 (pt) bactéria corineforme, e, método para produzir um l-aminoácido
BR112014012552A2 (pt) aparelho, e método
BR112013022820A2 (pt) método de tratamento
BR112014006670A2 (pt) aparelho, e método
BR112013022306A2 (pt) método, e, composição
BR112014011709A2 (pt) método, e aparelho
BR112014014285A2 (pt) composição, e, método para fabricar uma composição
CL2013002164A1 (es) Metodo para la obtencion de un insaponificable.
BR112014029487A2 (pt) método para o tratamento cosmético